COO: Share Buybacks And Merger Potential Will Drive Undervalued Stock Higher

Key Takeaways

• Resolving production constraints and launching innovative contact lens products position the company for strong revenue growth and market share gains, especially in premium and specialty segments.
  
• Automation, successful acquisitions, and cost discipline are expected to boost operating efficiency, margins, and free cash flow, supporting shareholder returns.
  
• Slowed market growth, competitive pricing pressure, product transition risks, and weak fertility and IUD segments threaten Cooper Companies' revenue, margin improvement, and growth prospects.

Catalysts

Develops, manufactures, and markets contact lens wearers.

• The company recently resolved its manufacturing constraints for MyDAY, its premium daily silicone hydrogel contact lens, and is now accelerating global rollout with expanded fitting sets, trial lenses, and over 30 new private label contracts. This is expected to drive substantial revenue growth and market share gains as pent-up demand is fulfilled and the premium offering captures higher margins over time.
  
• Cooper is launching several new innovative products-such as MyDAY Energys (targeting digital device users), MyDAY multifocal in new APAC markets, MyDAY MiSight (for myopia management), and expanded MiSight availability (including regulatory approval and launch in Japan). These product rollouts align with rising prevalence of myopia due to increased digital device use and an aging population requiring vision correction, providing strong upside for revenue in large, growing addressable markets.
  
• Investments in automation, digital solutions, and integration of recent acquisitions (notably in CooperSurgical and the fertility segment) are coming to fruition, leading to expected operating efficiencies, working capital improvements, and operating margin expansion-supporting higher future earnings and free cash flow conversion.
  
• Free cash flow is poised to inflect higher as a multi-year capital expenditure cycle winds down following the ramp-up of MyDAY capacity, with management guiding for approximately $2 billion in free cash flow over the next three years. This improved cash generation, tied to strong cost discipline and revenue momentum, will further benefit shareholders via debt reduction and share repurchases.
  
• Long-term market tailwinds-including increased healthcare access in emerging markets and the ongoing shift toward premium and specialty contact lenses (daily, silicone hydrogel, myopia management)-support sustained volume and pricing growth, which should positively impact both revenue and net margins as Cooper gains share in these faster-growing segments.

Cooper Companies Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Cooper Companies's revenue will grow by 5.4% annually over the next 3 years.
• Analysts assume that profit margins will increase from 9.7% today to 16.6% in 3 years time.
• Analysts expect earnings to reach $810.1 million (and earnings per share of $4.28) by about May 2029, up from $401.4 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as $982.5 million.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 25.8x on those 2029 earnings, down from 29.0x today. This future PE is greater than the current PE for the US Medical Equipment industry at 25.2x.
• Analysts expect the number of shares outstanding to decline by 2.2% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 8.0%, as per the Simply Wall St company report.

Risks

• Increasing competitive pricing pressure, especially in the Asia Pacific region, is causing Cooper Companies to lose low-margin e-commerce business and limit the company's ability to take pricing in key markets; this trend could result in industry-wide price compression and negatively impact overall revenue growth and margins.
  
• The transition from Clariti to MyDAY is causing unpredictable order patterns and a short-term revenue gap, with delayed revenue recognition from MyDAY's fitting and trial lens activity and uncertainty about if or when Clariti demand will recover; extended periods of soft sales could lead to weaker revenue growth and compressed margins.
  
• The global contact lens market's growth rate has slowed from 7% in 2021 to 4% in early 2025, partly due to faded price increases and possible consumer softness; if this deceleration persists, Cooper Companies could be capped at low-single-digit revenue growth, limiting upside potential for earnings and free cash flow.
  
• Heavy reliance on executing MyDAY's ramp-supported by new private label contracts and significant capacity investments-means if the fitting activity does not efficiently convert to sustained sales or market dynamics shift, planned revenue acceleration and margin improvements may fall short, risking underperformance versus expectations.
  
• Prolonged volatility and weakness in the fertility (CooperSurgical) and non-hormonal IUD (PARAGARD) markets, driven by delayed clinic capital purchases and declining IUD procedure volumes, could stall or reverse growth in these segments and drag on consolidated company revenues and net earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $91.07 for Cooper Companies based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $103.0, and the most bearish reporting a price target of just $69.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $4.9 billion, earnings will come to $810.1 million, and it would be trading on a PE ratio of 25.8x, assuming you use a discount rate of 8.0%.
• Given the current share price of $59.61, the analyst price target of $91.07 is 34.5% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.